← Leaderboards
Izidore S Lossos
University Of Miami School Of Medicine
$4,248,673
Attributed
$5,140,171
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $651.1K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,140,171 · 3
By mechanism
R01$5,140,171 · 3
Top collaborators
- Ramiro Ernesto Verdun5 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Ramiro Ernesto Verdun$3,654,446
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaTumorStructure Of Germinal Center Of Lymph NodeCellsLymphomaB-LymphocytesLeadMolecularBaseNovel TherapeuticsLarge Cell Diffuse Non-Hodgkin&AposBiologicalNon-Hodgkin&AposComplexAffectResponseLaboratoriesGenesImmune ResponseIn VivoNovel Therapeutic InterventionPathogenesisPrognosticPhysiological
Grant awards (18)
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL$352,286
R01 · FY2023 · CA · contact PI
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL$352,283
R01 · FY2022 · CA · contact PI
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL$359,476
R01 · FY2021 · CA · contact PI
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL$359,476
R01 · FY2020 · CA · contact PI
Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCL$359,476
R01 · FY2019 · CA · contact PI
Significance and Function of HGAL in Lymphoma$228,585
R01 · FY2013 · CA · contact PI
Significance and Function of HGAL in Lymphoma$243,175
R01 · FY2012 · CA · contact PI
Significance and Function of HGAL in Lymphoma$243,175
R01 · FY2011 · CA · contact PI
Prognostic Models in Diffuse Large B-Cell Lymphoma$318,726
R01 · FY2010 · CA · contact PI
Significance and Function of HGAL in Lymphoma$250,696
R01 · FY2010 · CA · contact PI
Significance and Function of HGAL in Lymphoma$36,000
R01 · FY2010 · CA · contact PI
Prognostic Models in Diffuse Large B-Cell Lymphoma$315,308
R01 · FY2009 · CA · contact PI
Significance and Function of HGAL in Lymphoma$263,946
R01 · FY2009 · CA · contact PI
Prognostic Models in Diffuse Large B-Cell Lymphoma$274,195
R01 · FY2008 · CA · contact PI
Prognostic Models in Diffuse Large B-Cell Lymphoma$395,777
R01 · FY2007 · CA · contact PI
Significance and Function of HGAL in Lymphoma$255,337
R01 · FY2007 · CA · contact PI
Significance and Function of HGAL in Lymphoma$262,963
R01 · FY2006 · CA · contact PI
Significance and Function of HGAL in Lymphoma$269,291
R01 · FY2005 · CA